A study was conducted to explore the effectiveness of as-needed second-generation antihistamines in patients having well-controlled urticaria under omalizumab therapy.
In individuals with well-controlled urticaria
under omalizumab therapy, the second-generation antihistamines are effective
agents to treat the intermittent symptoms of chronic spontaneous urticaria
(CSU).
A study was conducted to explore the
effectiveness of as-needed second-generation antihistamines in patients having
well-controlled urticaria under omalizumab therapy.
A total of 53 participants were enrolled in this study (38 females, mean age 41.1 ± 11.4 years). The study includes CSU patients who were given omalizumab therapy (300 mg/4 weeks for at least three months). These patients had well-controlled urticaria and were using second-generation antihistamines only if required.
Utilizing the
modified urticaria activity score-twice daily, the efficacy of
second-generation antihistamines, alteration in the hives, itch, and total
itch-hives scores prior to and after antihistamines were assessed.
The intake of second-generation antihistamines minimized itch, hives, and total itch-hives scores, as shown below:
As noted, the decline in the symptoms was comparable in both the
isolated-urticaria and urticaria and angioedema phenotypes. The baseline levels
of IgE were positively linked with the decline of the symptom scores. It
indicated that in people having a higher baseline total IgE levels,
administration of as-needed second-generation antihistamines lowered the
symptom scores less.
In CSU patients with
well-controlled urticaria under omalizumab therapy, the second-generation
antihistamines effectively decrease symptoms such as itch and hives. The baseline total
IgE levels may be utilized as a potential biomarker for the effectiveness of
these agents in urticaria patients.
Dermatologic therapy
Effectiveness of as-needed antihistamines in chronic spontaneous urticaria patients under omalizumab treatment
Murat Türk et al.
Comments (0)